SCHEMBL4104869

SCHEMBL4104869

Cc1ccc(Br)cc1N(C(=O)c1nc[nH]c1C(N)=O)c1nc2cc(F)ccc2[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215894 0.89 POLB (0.36) —
SCHEMBL214338 0.87 POLB (0.36) —
SCHEMBL214638 0.81 PARP1 (0.35) —
SCHEMBL215904 0.80 MAPT (0.35) —
SCHEMBL216492 0.79 POLB (0.37) —
SCHEMBL214939 0.78 POLB (0.36) —
SCHEMBL214752 0.78 BTK (0.32) —
SCHEMBL214715 0.77 POLB (0.40) —
SCHEMBL213661 0.77 TOP2A (0.33) —
SCHEMBL214140 0.77 POLB (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 — — EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 — — WO disclosed
Send feedback